Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Enalapril Maleate

FDA-approved product (tablet, oral), marketed as Enalapril Maleate, Epaned, Epaned Kit and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Enalapril Maleate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Congestive heart failure
  • Heart failure
  • Hypertension
  • Ventricular Dysfunction, Left

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Ace inhibitors, plain
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA33.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli22.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae14.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis69.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Enalapril Maleate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Enalapril Maleate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The Assessment of Partial Guideline-Directed Medical Therapy Down Titration in Heart Failure in Remission.

    NCT07513883 · start 2026-03-16

    Registered record
    Registry ID
    NCT07513883
    Conditions
    Heart Failure
    Interventions
    Down-titration; Continuation of guideline-directed heart failure therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-03-16
    Completion
    2028-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionDown-titration; Continuation of guideline-directed heart failure therapy
    PhasePhase 4
    Registry statusRecruiting

  • Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes

    NCT07568574 · start 2026-03-12

    Registered record
    Registry ID
    NCT07568574
    Conditions
    Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes
    Interventions
    Testosterone Enanthate; Testosterone Cypionate; Testosterone Propionate; Sustanon (testosterone); Testosterone Gel; Methenolone Enanthate (Primobolan); Nandrolone Decanoate (Deca-Durabolin); Estradiol Patch; Estradiol Capsule; Progesterone Cream; Progesterone Capsule; Human Growth Hormone (hGH); EPO Darbepoetin (Aranesp); Meldonium; Modafinil; Mixed amphetamine salts (Adderall); Clomiphene; Anastrozole; Levothyroxine; Liothyronine; hCG; hMG; Atorvastatin; Rosuvastatin; Bisoprolol; Nebivolol; Metoprolol; Propranolol; Lisinopril; Enalapril; Furosemide; Chlorothiazide; Cabergoline; Metformin; Basal Insulin Glargine (long-acting); Telmisartan; Losartan
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Enrolling by invitation
    Start
    2026-03-12
    Completion
    2033-03-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSafety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes
    InterventionTestosterone Enanthate; Testosterone Cypionate; Testosterone Propionate; Sustanon (testosterone) +33 more
    PhaseNot applicable
    Registry statusEnrolling by invitation

  • Postpartum Evaluation of Nifedipine and Enalapril for Hypertension

    NCT07023003 · start 2025-07-11

    Registered record
    Registry ID
    NCT07023003
    Conditions
    Hypertension in Pregnancy
    Interventions
    Enalapril 10mg QD; Nifedipine 30mg XL BID
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-07-11
    Completion
    2028-12
    Enrolment
    850

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension in Pregnancy
    InterventionEnalapril 10mg QD; Nifedipine 30mg XL BID
    PhasePhase 4
    Registry statusRecruiting

  • Treatment of Patients With Diabetic Kidney Disease

    NCT06187493 · start 2024-01-01

    Registered record
    Registry ID
    NCT06187493
    Conditions
    Diabetic Kidney Disease
    Interventions
    lisinopril, enalapril; dapagliflozin, empagliflozin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2024-01-01
    Completion
    2025-12-31
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Kidney Disease
    Interventionlisinopril, enalapril; dapagliflozin, empagliflozin
    PhaseNot applicable
    Registry statusUnknown

  • Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension

    NCT05593055 · start 2023-08-25

    Registered record
    Registry ID
    NCT05593055
    Conditions
    Hypertension; Left Ventricular Hypertrophy
    Interventions
    Eplerenone; Chlorthalidone; Potassium
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2023-08-25
    Completion
    2027-12-31
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Left Ventricular Hypertrophy
    InterventionEplerenone; Chlorthalidone; Potassium
    PhasePhase 4
    Registry statusRecruiting

  • Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease

    NCT05373004 · start 2023-03

    Registered record
    Registry ID
    NCT05373004
    Conditions
    Diabetic Nephropathy Type 2
    Interventions
    Empagliflozin 25 MG; Enalapril Maleate 20 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2023-03
    Completion
    2024-05
    Enrolment
    212

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Nephropathy Type 2
    InterventionEmpagliflozin 25 MG; Enalapril Maleate 20 mg
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Feasibility Study of a Novel mHealth Application to Enable Community Health Workers to Manage

    NCT05479097 · start 2023-02-06

    Registered record
    Registry ID
    NCT05479097
    Conditions
    Hypertension
    Interventions
    Anti-Hypertensive
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2023-02-06
    Completion
    2023-12-31
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionAnti-Hypertensive
    PhaseNot applicable
    Registry statusCompleted

  • Pulmonary REsistance Modification Under Treatment With Sacubitril/valsartaN in paTients With Heart Failure With Reduced Ejection Fraction

    NCT05487261 · start 2022-12-13

    Registered record
    Registry ID
    NCT05487261
    Conditions
    Heart Failure
    Interventions
    Sacubitril-valsartan; Enalapril; placebo; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-12-13
    Completion
    2025-11
    Enrolment
    260

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionSacubitril-valsartan; Enalapril; placebo; Placebo
    PhasePhase 4
    Registry statusUnknown

  • The Effect of Enalapril, Losartan or Not Antihypertensive on the Oxidative Status in Renal Transplant Recipients

    NCT05232370 · start 2022-01-01

    Registered record
    Registry ID
    NCT05232370
    Conditions
    Oxidative Stress
    Interventions
    Angiotensin converting enzyme inhibitor; Angiotensin Receptor Blockers
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-01-01
    Completion
    2022-01-06
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOxidative Stress
    InterventionAngiotensin converting enzyme inhibitor; Angiotensin Receptor Blockers
    PhasePhase 2
    Registry statusCompleted

  • Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)

    NCT04937907 · start 2021-09-08

    Registered record
    Registry ID
    NCT04937907
    Conditions
    Alport Syndrome, X-Linked
    Interventions
    Hydroxychloroquine Sulfate 100 milligram (mg) Tab; Benazepril hydrochloride 10 milligram (mg) Tab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-09-08
    Completion
    2024-12-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlport Syndrome, X-Linked
    InterventionHydroxychloroquine Sulfate 100 milligram (mg) Tab; Benazepril hydrochloride 10 milligram (mg) Tab
    PhasePhase 2
    Registry statusCompleted

  • Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF.

    NCT04853758 · start 2021-05-06

    Registered record
    Registry ID
    NCT04853758
    Conditions
    Chagas Cardiomyopathy
    Interventions
    Sacubitril / Valsartan Oral Tablet [Entresto]; Enalapril
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2021-05-06
    Completion
    2024-12-01
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChagas Cardiomyopathy
    InterventionSacubitril / Valsartan Oral Tablet [Entresto]; Enalapril
    PhasePhase 3
    Registry statusUnknown

  • COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure

    NCT03917459 · start 2019-04-16

    Registered record
    Registry ID
    NCT03917459
    Conditions
    Heart Failure; Heart Failure, Systolic; Erectile Dysfunction
    Interventions
    LCZ696; Enalapril matching placebo; Enalapril; LCZ696 matching placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-04-16
    Completion
    2021-05-25
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure; Heart Failure, Systolic; Erectile Dysfunction
    InterventionLCZ696; Enalapril matching placebo; Enalapril; LCZ696 matching placebo
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy

    NCT03502031 · start 2018-10-01

    Registered record
    Registry ID
    NCT03502031
    Conditions
    Renal Insufficiency, Chronic; Diabetic Nephropathy Type 2
    Interventions
    Renin-Angiotensin (RAAS) alone; Renin-Angiotensin (RAAS) blockers in combination with Spironolactone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2018-10-01
    Completion
    2024-10-01
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Insufficiency, Chronic; Diabetic Nephropathy Type 2
    InterventionRenin-Angiotensin (RAAS) alone; Renin-Angiotensin (RAAS) blockers in combination with Spironolactone
    PhasePhase 4
    Registry statusUnknown

  • Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2

    NCT03005184 · start 2017-09

    Registered record
    Registry ID
    NCT03005184
    Conditions
    Heart Failure NYHA Class I; Heart Failure NYHA Class II; Heart Failure NYHA Class III
    Interventions
    Valsartan 80 mg bid; Enalapril 10 mg bid; Sacubitril-Valsartan 200 mg bid; Icatibant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2017-09
    Completion
    2020-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure NYHA Class I; Heart Failure NYHA Class II; Heart Failure NYHA Class III
    InterventionValsartan 80 mg bid; Enalapril 10 mg bid; Sacubitril-Valsartan 200 mg bid; Icatibant +1 more
    PhasePhase 2
    Registry statusWithdrawn

  • The Effect of Neprilysin (LCZ696) on Exercise Tolerance in Patients With Heart Failure

    NCT03190304 · start 2017-06-14

    Registered record
    Registry ID
    NCT03190304
    Conditions
    Heart Failure; Exercise Tolerance; Vasodilation; Body Composition; Muscle Strength
    Interventions
    Neprilysin; Enalapril
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-06-14
    Completion
    2020-09-23
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure; Exercise Tolerance; Vasodilation; Body Composition +1 more
    InterventionNeprilysin; Enalapril
    PhasePhase 4
    Registry statusCompleted